Understanding the rate of lymphocyte replication and destruction in HIV-infected patients, as well as the effects of therapy on lymphocyte replication should lead to a better understanding of the mechanisms behind the immunodeficiency induced by HIV. Little is known about the replication rate in healthy and HIV-infected patients. Two approaches are being used to address this issue. (1) Healthy and HIV-infected patients will receive up to 5 days of continuous infusions with [6,6-2H2]-glucose, a nonradioactive, stable isotope of glucose that is safe to administer. The deuterium is incorporated into DNA via metabolism of glucose to ribose and incorporation into nucleotides. The rate of incorporation can be measured in subpopulations of cells to determine the rate of replication of those cells, and the rate of loss of the incorporated deuterium can be used to examine the turnover rate of the replicated cells. (2) Administering bromodeoxyuridine (BrDU; 200 mg/m2), an analogue of thymidine, to HIV-infected patients. BrDU is incorporated into DNA and incorporation can be measured using an anti-BrDU monoclonal antibody. By FACS analysis, both surface markers and BrDU can be measured. Thus, FACS analysis can be used to directly measure subpopulations of cells that have replicated. To date, 50 patients have been enrolled in these studies. Techniques for measuring incorporation have been developed and validated for both methods. Studies with BrDU have identified two populationsof proliferating cells, one with a rapid turnover, and the second with a slow turnover. The size of the rapidly proliferating pool, but not the slowly proliferating pool, is directly related to the log viral load, suggesting that HIV drives cells to enter the rapidly proliferating pool. Over the past year we have examined lymphocyte kinetics in patients receiving IL-2, and have found that intermittent IL-2 therapy expands both CD4 and CD8 cells, which then have a very long survival in responding patients. Studies are ongoing to follow up on these observations and to evaluate lymphocyte replication in other settings. These two approaches should provide information about lymphocyte kinetics that will have relevance to HIV infection and other disease states.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL000191-05
Application #
6675151
Study Section
(CCM)
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Read, Sarah W; Lempicki, Richard A; Di Mascio, Michele et al. (2008) CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients. J Infect Dis 198:843-50
Di Mascio, Michele; Sereti, Irini; Matthews, Lynn T et al. (2006) Naive T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion. J Virol 80:2665-74
Kovacs, Joseph A; Lempicki, Richard A; Sidorov, Igor A et al. (2005) Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 115:2139-48
Natarajan, Ven; Lempicki, Richard A; Sereti, Irini et al. (2002) Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection. Proc Natl Acad Sci U S A 99:10712-7
Kovacs, J A; Lempicki, R A; Sidorov, I A et al. (2001) Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med 194:1731-41
Sereti, I; Herpin, B; Metcalf, J A et al. (2001) CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. AIDS 15:1765-75
Lempicki, R A; Kovacs, J A; Baseler, M W et al. (2000) Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proc Natl Acad Sci U S A 97:13778-83